

# Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus controlled with metformin and sulphonylurea: a randomised controlled trial

International Journal of Clinical Practice

67, 1267-1282

DOI: [10.1111/ijcp.12322](https://doi.org/10.1111/ijcp.12322)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Pharmacodynamic Effects of Canagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor, from a Randomized Study in Patients with Type 2 Diabetes. PLoS ONE, 2014, 9, e105638.	1.1	53
2	Update on developments with SGLT2 inhibitors in the management of type 2 diabetes. Drug Design, Development and Therapy, 2014, 8, 1335.	2.0	279
3	Novel and emerging diabetes mellitus drug therapies for the type 2 diabetes patient. World Journal of Diabetes, 2014, 5, 305.	1.3	20
4	Sodium-glucose co-transporter 2 (SGLT2) inhibitors: a growing class of antidiabetic agents. Drugs in Context, 2014, 3, 1-19.	1.0	40
5	A safety evaluation of canagliflozin: a first-in-class treatment for type 2 diabetes. Expert Opinion on Drug Safety, 2014, 13, 1535-1544.	1.0	8
6	Effect of Canagliflozin on Blood Pressure and Adverse Events Related to Osmotic Diuresis and Reduced Intravascular Volume in Patients With Type 2 Diabetes Mellitus. Journal of Clinical Hypertension, 2014, 16, 875-882.	1.0	95
7	The potential role of sodium glucose co-transporter 2 inhibitors in combination therapy for type 2 diabetes mellitus. Expert Opinion on Pharmacotherapy, 2014, 15, 2565-2585.	0.9	27
8	Genital mycotic infections with canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus: a pooled analysis of clinical studies. Current Medical Research and Opinion, 2014, 30, 1109-1119.	0.9	124
9	The Impact of Weight Loss on Weight-related Quality of Life and Health Satisfaction: Results From a Trial Comparing Canagliflozin With Sitagliptin in Triple Therapy Among People With Type 2 Diabetes. Postgraduate Medicine, 2014, 126, 7-15.	0.9	26
10	Canagliflozin, a Sodium Glucose Co-transporter 2 Inhibitor, for the Management of Type 2 Diabetes. Hospital Practice (1995), 2014, 42, 96-108.	0.5	6
11	Canagliflozin, a sodium glucose co-transporter 2 inhibitor, reduces post-meal glucose excursion in patients with type 2 diabetes by a non-renal mechanism: results of a randomized trial. Metabolism: Clinical and Experimental, 2014, 63, 1296-1303.	1.5	43
12	Urinary Tract Infection in Randomized Phase III Studies of Canagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor. Postgraduate Medicine, 2014, 126, 7-17.	0.9	71
13	Safety and Tolerability of Canagliflozin in Patients With Type 2 Diabetes Mellitus: Pooled Analysis of Phase 3 Study Results. Postgraduate Medicine, 2014, 126, 16-34.	0.9	82
14	SGLT2 inhibitors: New medicines for addressing unmet needs in type 2 diabetes. Australasian Medical Journal, 2014, 7, 405-415.	0.1	34
15	Efficacy and Safety of Canagliflozin in Patients with Type 2 Diabetes and Stage 3 Nephropathy. American Journal of Nephrology, 2014, 40, 64-74.	1.4	106
16	Sodium glucose transporter protein 2 inhibitors: focusing on the kidney to treat type 2 diabetes. Therapeutic Advances in Endocrinology and Metabolism, 2014, 5, 124-136.	1.4	29
17	Effect of the sodium glucose co-transporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitus. Diabetes, Obesity and Metabolism, 2014, 16, 1087-1095.	2.2	204
18	Sodium glucose co-transporter 2 inhibitors: A novel approach to the management of type 2 diabetes mellitus. Journal of the American Association of Nurse Practitioners, 2014, 26, 356-363.	0.5	7

#	ARTICLE	IF	CITATIONS
19	Effect of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, on measurement of serum 1,5-anhydroglucitol (1,5-AG). <i>Diabetes Care</i> , 2014, 37, 1146-1150.	0.8	22
20	Ramping Glucosuria for Management of Type 2 Diabetes Mellitus: An Emerging Cynosure. <i>Medicinal Research Reviews</i> , 2014, 34, 1146-1167.	5.0	9
21	A Novel Therapeutic Agent for Type 2 Diabetes Mellitus: SGLT2 Inhibitor. <i>Diabetes and Metabolism Journal</i> , 2014, 38, 261.	1.8	66
22	Effect of canagliflozin on serum electrolytes in patients with type 2 diabetes in relation to estimated glomerular filtration rate (eGFR). <i>Current Medical Research and Opinion</i> , 2014, 30, 1759-1768.	0.9	94
23	Canagliflozin. <i>Cardiology in Review</i> , 2014, 22, 97-104.	0.6	8
24	Sodium Glucose Co-Transporter 2 Inhibitors and Their Mechanism for Improving Glycemia in Patients with Type 2 Diabetes. <i>Postgraduate Medicine</i> , 2014, 126, 33-48.	0.9	40
25	Canagliflozin, a sodium glucose co-transporter 2 inhibitor, improves model-based indices of beta cell function in patients with type 2 diabetes. <i>Diabetologia</i> , 2014, 57, 891-901.	2.9	96
26	Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone. <i>Diabetes, Obesity and Metabolism</i> , 2014, 16, 467-477.	2.2	228
27	Efficacy and safety of twice-daily treatment with canagliflozin, a sodium glucose co-transporter 2 inhibitor, added on to metformin monotherapy in patients with type 2 diabetes mellitus. <i>Journal of Clinical and Translational Endocrinology</i> , 2014, 1, 54-60.	1.0	26
28	Effects of Hydrochlorothiazide on the Pharmacokinetics, Pharmacodynamics, and Tolerability of Canagliflozin, a Sodium Glucose Co-transporter 2 Inhibitor, in Healthy Participants. <i>Clinical Therapeutics</i> , 2014, 36, 698-710.	1.1	46
29	The role of the kidneys in glucose homeostasis in type 2 diabetes: Clinical implications and therapeutic significance through sodium glucose co-transporter 2 inhibitors. <i>Metabolism: Clinical and Experimental</i> , 2014, 63, 1228-1237.	1.5	139
30	Efficacy and safety of canagliflozin in subjects with type 2 diabetes: systematic review and meta-analysis. <i>European Journal of Clinical Pharmacology</i> , 2014, 70, 1149-1158.	0.8	106
31	Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease. <i>Diabetes, Obesity and Metabolism</i> , 2014, 16, 1016-1027.	2.2	220
32	Canagliflozin: A Review of Its Use in Patients with Type 2 Diabetes Mellitus. <i>Drugs</i> , 2014, 74, 807-824.	4.9	59
33	Efficacy and safety of canagliflozin compared with placebo in older patients with type 2 diabetes mellitus: a pooled analysis of clinical studies. <i>BMC Endocrine Disorders</i> , 2014, 14, 37.	0.9	80
34	SGLT2 inhibitors in the treatment of type 2 diabetes. <i>Diabetes Research and Clinical Practice</i> , 2014, 104, 297-322.	1.1	139
35	Blood pressure effects of sodium-glucose co-transport 2 (SGLT2) inhibitors. <i>Journal of the American Society of Hypertension</i> , 2014, 8, 330-339.	2.3	201
36	Emerging Pharmacotherapies to Fight Obesity and Related Disorders. <i>Journal of Obesity &amp; Weight Loss Therapy</i> , 2014, 04, .	0.1	3

#	ARTICLE	IF	CITATIONS
37	Canagliflozin: a sodium glucose co-transporter 2 inhibitor for the treatment of type 2 diabetes mellitus. <i>Annals of the New York Academy of Sciences</i> , 2015, 1358, 28-43.	1.8	75
38	The potential role of sodium glucose co-transporter 2 inhibitors in the early treatment of type 2 diabetes mellitus. <i>International Journal of Clinical Practice</i> , 2015, 69, 1071-1087.	0.8	29
39	Canagliflozin Treatment in Patients with Type 2 Diabetes Mellitus. <i>Clinical Medicine Insights: Endocrinology and Diabetes</i> , 2015, 8, CMED.S31526.	1.0	18
40	Sodium-glucose cotransporter-2 inhibitors and blood pressure decrease. <i>Journal of Hypertension</i> , 2015, 33, 2185-2197.	0.3	60
41	Characteristics and outcomes of patients with type 2 diabetes mellitus treated with canagliflozin: a real-world analysis. <i>BMC Endocrine Disorders</i> , 2015, 15, 67.	0.9	19
42	Durability and tolerability of dapagliflozin over 52-weeks as add-on to metformin and sulphonylurea in type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2015, 17, 1075-1084.	2.2	52
43	New treatments for type 2 diabetes: are we any closer to reducing iatrogenic hypoglycaemia?. <i>Practical Diabetes</i> , 2015, 32, 291.	0.1	0
44	Efficacy and safety of antihyperglycaemic drug regimens added to metformin and sulphonylurea therapy in Type 2 diabetes: a network meta-analysis. <i>Diabetic Medicine</i> , 2015, 32, 1530-1540.	1.2	40
45	Triple therapy in type 2 diabetes; a systematic review and network meta-analysis. <i>PeerJ</i> , 2015, 3, e1461.	0.9	37
46	Clinical Pharmacokinetic, Pharmacodynamic, and Drug-Drug Interaction Profile of Canagliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor. <i>Clinical Pharmacokinetics</i> , 2015, 54, 1027-1041.	1.6	83
47	The Importance of Weight Change Experiences for Performance of Diabetes Self-Care: A Patient-Centered Approach to Evaluating Clinical Outcomes in Type 2 Diabetes. <i>Diabetes Therapy</i> , 2015, 6, 611-625.	1.2	10
48	Efficacy and Safety of Canagliflozin, an Inhibitor of Sodium-Glucose Cotransporter 2, When Used in Conjunction With Insulin Therapy in Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2015, 38, 403-411.	4.3	196
49	Pharmacologic Treatment of Type 2 Diabetes. <i>Annals of Pharmacotherapy</i> , 2015, 49, 540-556.	0.9	69
50	Dapagliflozin Improves Glycemic Control and Reduces Body Weight as Add-on Therapy to Metformin Plus Sulfonylurea: A 24-Week Randomized, Double-Blind Clinical Trial. <i>Diabetes Care</i> , 2015, 38, 365-372.	4.3	115
51	SGLT-2 Inhibitors: Potential Novel Strategy to Prevent Congestive Heart Failure in Diabetes?. <i>Current Cardiovascular Risk Reports</i> , 2015, 9, 1.	0.8	7
52	Effect of food on the pharmacokinetics of canagliflozin/metformin (150/1,000 mg) immediate-release fixed-dose combination tablet in healthy participants. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2015, 53, 256-264.	0.3	12
53	Energy Balance After Sodium-Glucose Cotransporter 2 Inhibition. <i>Diabetes Care</i> , 2015, 38, 1730-1735.	4.3	276
54	The efficacy and safety of canagliflozin across racial groups in patients with type 2 diabetes mellitus. <i>Current Medical Research and Opinion</i> , 2015, 31, 1693-1702.	0.9	16

#	ARTICLE	IF	CITATIONS
55	Diabetic Ketoacidosis and Related Events in the Canagliflozin Type 2 Diabetes Clinical Program. <i>Diabetes Care</i> , 2015, 38, 1680-1686.	4.3	278
56	Cost-Effectiveness of Canagliflozin versus Sitagliptin as Add-on to Metformin in Patients with Type 2 Diabetes Mellitus in Mexico. <i>Value in Health Regional Issues</i> , 2015, 8, 8-19.	0.5	17
57	Efficacy and safety of canagliflozin by baseline HbA1c and known duration of type 2 diabetes mellitus. <i>Journal of Diabetes and Its Complications</i> , 2015, 29, 438-444.	1.2	43
58	Clinical Implications of Canagliflozin Treatment in Patients With Type 2 Diabetes. <i>Clinical Diabetes</i> , 2015, 33, 5-13.	1.2	5
60	Effect of Hepatic or Renal Impairment on the Pharmacokinetics of Canagliflozin, a Sodium Glucose Co-transporter 2 Inhibitor. <i>Clinical Therapeutics</i> , 2015, 37, 610-628.e4.	1.1	38
61	Effects of canagliflozin on body weight and relationship to HbA1c and blood pressure changes in patients with type 2 diabetes. <i>Diabetologia</i> , 2015, 58, 1183-1187.	2.9	118
62	The Role of Sodium-Glucose Co-Transporter 2 Inhibitors in the Treatment of Type 2 Diabetes. <i>Clinical Therapeutics</i> , 2015, 37, 1150-1166.	1.1	74
63	Cardiometabolic Effects of a New Class of Antidiabetic Agents. <i>Clinical Therapeutics</i> , 2015, 37, 1178-1194.	1.1	39
64	Effect of canagliflozin on the pharmacokinetics of glyburide, metformin, and simvastatin in healthy participants. <i>Clinical Pharmacology in Drug Development</i> , 2015, 4, 226-236.	0.8	17
65	Canagliflozin for the treatment of adults with Type 2 diabetes. <i>Diabetes Management</i> , 2015, 5, 183-201.	0.5	9
66	Achievement of treatment goals with canagliflozin in patients with type 2 diabetes mellitus: a pooled analysis of randomized controlled trials. <i>Current Medical Research and Opinion</i> , 2015, 31, 1993-2000.	0.9	10
67	Efficacy and safety of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes: a meta-analysis of randomized controlled trials for 1 to 2 years. <i>Journal of Diabetes and Its Complications</i> , 2015, 29, 1295-1303.	1.2	115
68	Renal effects of canagliflozin in type 2 diabetes mellitus. <i>Current Medical Research and Opinion</i> , 2015, 31, 2219-2231.	0.9	49
69	Clinical use of dipeptidyl peptidase-4 and sodium-glucose cotransporter 2 inhibitors in combination therapy for type 2 diabetes mellitus. <i>Postgraduate Medicine</i> , 2015, 127, 463-479.	0.9	11
70	Sodium-Glucose Cotransporter 2 Inhibitors in the Treatment of Type 2 Diabetes Mellitus. <i>The Diabetes Educator</i> , 2015, 41, 5S-18S.	2.6	4
71	Efficacy and tolerability of canagliflozin as add-on to metformin in the treatment of type 2 diabetes mellitus: a meta-analysis. <i>European Journal of Clinical Pharmacology</i> , 2015, 71, 1325-1332.	0.8	25
72	Efficacy and Safety of Canagliflozin Used in Conjunction with Sulfonylurea in Patients with Type 2 Diabetes Mellitus: A Randomized, Controlled Trial. <i>Diabetes Therapy</i> , 2015, 6, 289-302.	1.2	36
73	Randomized, Double-Blind, Phase 3 Trial of Triple Therapy With Dapagliflozin Add-on to Saxagliptin Plus Metformin in Type 2 Diabetes. <i>Diabetes Care</i> , 2015, 38, 2009-2017.	4.3	106

#	ARTICLE	IF	CITATIONS
74	Pharmacodynamic differences between canagliflozin and dapagliflozin: results of a randomized, double-blind, crossover study. <i>Diabetes, Obesity and Metabolism</i> , 2015, 17, 188-197.	2.2	80
75	Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55-80 years with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2015, 17, 294-303.	2.2	177
76	Pharmacodynamics, Efficacy and Safety of Sodium-Glucose Co-Transporter Type 2 (SGLT2) Inhibitors for the Treatment of Type 2 Diabetes Mellitus. <i>Drugs</i> , 2015, 75, 33-59.	4.9	417
77	Canagliflozin Provides Durable Glycemic Improvements and Body Weight Reduction Over 104 Weeks Versus Glimepiride in Patients With Type 2 Diabetes on Metformin: A Randomized, Double-Blind, Phase 3 Study. <i>Diabetes Care</i> , 2015, 38, 355-364.	4.3	197
78	Canagliflozin in Asian patients with type 2 diabetes on metformin alone or metformin in combination with sulphonylurea. <i>Diabetes, Obesity and Metabolism</i> , 2015, 17, 23-31.	2.2	73
79	An overview of the effect of sodium glucose cotransporter 2 inhibitor monotherapy on glycemic and other clinical laboratory parameters in type 2 diabetes patients. <i>Therapeutics and Clinical Risk Management</i> , 2016, Volume 12, 1113-1131.	0.9	19
80	Impact of sodium&ndash;glucose cotransporter 2 inhibitors on blood pressure. <i>Vascular Health and Risk Management</i> , 2016, Volume 12, 393-405.	1.0	51
81	Efficacy and Safety of Canagliflozin in Patients With Type 2 Diabetes Mellitus of Different Ethnicity. <i>Ethnicity and Disease</i> , 2016, 26, 221.	1.0	9
82	Benefits and Harms of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis. <i>PLoS ONE</i> , 2016, 11, e0166125.	1.1	188
83	Euglycemic Diabetic Ketoacidosis in a 27 year-old female patient with type-1-Diabetes treated with sodium-glucose cotransporter-2 (SGLT2) inhibitor Canagliflozin. <i>Pakistan Journal of Medical Sciences</i> , 2016, 32, 786-8.	0.3	16
84	The placebo response of injectable GLP-1 receptor agonists <i>vs</i>. oral DPP-4 inhibitors and SGLT-2 inhibitors: a systematic review and meta-analysis. <i>British Journal of Clinical Pharmacology</i> , 2016, 82, 301-314.	1.1	22
85	Canagliflozin provides greater attainment of both HbA1c and body weight reduction versus sitagliptin in patients with type 2 diabetes. <i>Postgraduate Medicine</i> , 2016, 128, 725-730.	0.9	11
86	Energy balance and metabolic changes with sodium&glucose co&transporter 2 inhibition. <i>Diabetes, Obesity and Metabolism</i> , 2016, 18, 125-134.	2.2	76
87	Benefits/Risks of Sodium&Glucose Co-Transporter 2 Inhibitor Canagliflozin in Women for the Treatment of Type 2 Diabetes. <i>Women's Health</i> , 2016, 12, 379-388.	0.7	16
88	Glycaemic efficacy of canagliflozin is largely independent of baseline $\beta$ -cell function or insulin sensitivity. <i>Diabetic Medicine</i> , 2016, 33, 1744-1747.	1.2	7
90	Triple therapy combinations for the treatment of type 2 diabetes - A network meta-analysis. <i>Diabetes Research and Clinical Practice</i> , 2016, 116, 149-158.	1.1	31
91	Real-world Canagliflozin Utilization: Glycemic Control Among Patients With Type 2 Diabetes Mellitus - A Multi-Database Synthesis. <i>Clinical Therapeutics</i> , 2016, 38, 2071-2082.	1.1	7
92	Canagliflozin: Efficacy and Safety in Combination with Metformin Alone or with Other Antihyperglycemic Agents in Type 2 Diabetes. <i>Diabetes Therapy</i> , 2016, 7, 659-678.	1.2	6

#	ARTICLE	IF	CITATIONS
93	Glucose renal excretion as diabetes treatment: From an old diagnostic method to a new way of treatment. <i>Medicina Clínica (English Edition)</i> , 2016, 146, 460-464.	0.1	0
94	New Oral Hypoglycemic Agents and Cardiovascular Risk. Crossing the Metabolic Border. <i>Revista Espanola De Cardiologia (English Ed )</i> , 2016, 69, 1088-1097.	0.4	4
95	Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus living in hot climates. <i>International Journal of Clinical Practice</i> , 2016, 70, 775-785.	0.8	17
96	Sodium glucose CoTransporter 2 (SGLT2) inhibitors: Current status and future perspective. <i>European Journal of Pharmaceutical Sciences</i> , 2016, 93, 244-252.	1.9	70
97	Efficacy and safety of titrated canagliflozin in patients with type 2 diabetes mellitus inadequately controlled on metformin and sitagliptin. <i>Diabetes, Obesity and Metabolism</i> , 2016, 18, 812-819.	2.2	49
98	Efficacy of canagliflozin combined with antidiabetic drugs in treating type 2 diabetes mellitus: Meta-analysis of randomized control trials. <i>Journal of Diabetes Investigation</i> , 2016, 7, 359-365.	1.1	6
99	Efficacy and safety of canagliflozin when used in conjunction with incretin mimetic therapy in patients with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2016, 18, 82-91.	2.2	74
100	Efficacy and Safety of Canagliflozin in Individuals Aged 75 and Older with Type 2 Diabetes Mellitus: A Pooled Analysis. <i>Journal of the American Geriatrics Society</i> , 2016, 64, 543-552.	1.3	64
101	Glycemic Control Outcomes After Canagliflozin Initiation: Observations in a Medicare and Commercial Managed Care Population in Clinical Practice. <i>Clinical Therapeutics</i> , 2016, 38, 2046-2057.e2.	1.1	9
102	Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors and Cardiovascular Disease: A Systematic Review. <i>Cardiology and Therapy</i> , 2016, 5, 161-168.	1.1	17
103	Elevated serum magnesium associated with SGLT2 inhibitor use in type 2 diabetes patients: a meta-analysis of randomised controlled trials. <i>Diabetologia</i> , 2016, 59, 2546-2551.	2.9	95
104	Efficacy and safety of triple therapy with dapagliflozin addition to saxagliptin plus metformin over 52 weeks in patients with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2016, 18, 1134-1137.	2.2	52
105	Nuevos hipoglucemiantes orales y riesgo cardiovascular. Cruzando la frontera metabólica. <i>Revista Espanola De Cardiologia</i> , 2016, 69, 1088-1097.	0.6	13
106	Clinical Effectiveness and Impact on Insulin Therapy Cost After Addition of Dapagliflozin to Patients with Uncontrolled Type 2 Diabetes. <i>Diabetes Therapy</i> , 2016, 7, 765-776.	1.2	10
107	Efficacy and safety of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , 2016, 18, 783-794.	2.2	355
108	Effect of Sodium-Glucose Cotransporter 2 Inhibitors on Diabetic Ketoacidosis Among Patients With Type 2 Diabetes: A Meta-analysis of Randomized Controlled Trials. <i>Diabetes Care</i> , 2016, 39, e123-e124.	4.3	56
109	SGLT2 inhibitors in the management of type 2 diabetes. <i>Endocrine</i> , 2016, 53, 364-372.	1.1	64
110	Initial Combination Therapy With Canagliflozin Plus Metformin Versus Each Component as Monotherapy for Drug-Naïve Type 2 Diabetes. <i>Diabetes Care</i> , 2016, 39, 353-362.	4.3	105

#	ARTICLE	IF	CITATIONS
111	Evaluation of Bone Mineral Density and Bone Biomarkers in Patients With Type 2 Diabetes Treated With Canagliflozin. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 44-51.	1.8	212
112	Efficacy and safety of canagliflozin in type 2 diabetes mellitus: systematic review of randomized controlled trials. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 105-115.	0.9	10
113	Sodium-glucose cotransporter-2 inhibitors and genital and urinary tract infections in type 2 diabetes. <i>Postgraduate Medicine</i> , 2016, 128, 409-417.	0.9	34
114	Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis. <i>Lancet Diabetes and Endocrinology</i> , 2016, 4, 411-419.	5.5	384
115	Sodium-glucose cotransporter 2 inhibitors and cardiovascular outcomes. <i>Postgraduate Medicine</i> , 2016, 128, 398-408.	0.9	2
116	Effects of canagliflozin on body weight and body composition in patients with type 2 diabetes over 104 weeks. <i>Postgraduate Medicine</i> , 2016, 128, 371-380.	0.9	55
117	Impact of Age and Estimated Glomerular Filtration Rate on the Glycemic Efficacy and Safety of Canagliflozin: A Pooled Analysis of Clinical Studies. <i>Canadian Journal of Diabetes</i> , 2016, 40, 247-257.	0.4	18
118	Sodium-glucose cotransporter 2 inhibitors: an evidence-based practice approach to their use in the natural history of type 2 diabetes. <i>Current Medical Research and Opinion</i> , 2016, 32, 907-919.	0.9	11
119	The kidney and type 2 diabetes mellitus: therapeutic implications of SGLT2 inhibitors. <i>Postgraduate Medicine</i> , 2016, 128, 290-298.	0.9	24
120	Practical considerations for the use of sodium-glucose co-transporter type 2 inhibitors in treating hyperglycemia in type 2 diabetes. <i>Current Medical Research and Opinion</i> , 2016, 32, 1097-1108.	0.9	14
121	Network meta-analysis of treatments for type 2 diabetes mellitus following failure with metformin plus sulfonylurea. <i>Current Medical Research and Opinion</i> , 2016, 32, 807-816.	0.9	32
122	Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 157-166.	1.8	356
123	Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus from Latin America. <i>Current Medical Research and Opinion</i> , 2016, 32, 427-439.	0.9	7
124	Effect of canagliflozin on liver function tests in patients with type 2 diabetes. <i>Diabetes and Metabolism</i> , 2016, 42, 25-32.	1.4	107
125	Dapagliflozin combination therapy in type 2 diabetes mellitus. <i>Postgraduate Medicine</i> , 2016, 128, 124-136.	0.9	3
126	SGLT2 inhibitors. <i>Biochemical Pharmacology</i> , 2016, 101, 27-39.	2.0	27
127	Pharmacotherapy of insulin-treatment resistant type 2 diabetes. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 503-515.	0.9	29
128	Metabolic and hemodynamic effects of sodium-dependent glucose cotransporter 2 inhibitors on cardio-renal protection in the treatment of patients with type 2 diabetes mellitus. <i>Journal of Diabetes Investigation</i> , 2017, 8, 416-427.	1.1	59



#	ARTICLE	IF	CITATIONS
129	Effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on blood pressure and markers of arterial stiffness in patients with type 2 diabetes mellitus: a post hoc analysis. <i>Cardiovascular Diabetology</i> , 2017, 16, 29.	2.7	80
130	Adverse drug events observed in patients with type 2 diabetes mellitus treated with 100Âmg versus 300Âmg canagliflozin: a systematic review and meta-analysis of published randomized controlled trials. <i>BMC Pharmacology &amp; Toxicology</i> , 2017, 18, 19.	1.0	7
131	Real-world Clinical Outcomes Among Patients With Type 2 Diabetes Receiving Canagliflozin at a Specialty Diabetes Clinic: Subgroup Analysis by Baseline HbA 1c and Age. <i>Clinical Therapeutics</i> , 2017, 39, 1123-1131.	1.1	11
132	Sodium-glucose co-transporter 2 inhibitors for type 2 diabetes mellitus: An overview for the primary care physician. <i>International Journal of Clinical Practice</i> , 2017, 71, e12937.	0.8	22
133	Bone effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus. <i>Postgraduate Medicine</i> , 2017, 129, 159-168.	0.9	31
134	SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease. <i>Cardiovascular Diabetology</i> , 2017, 16, 65.	2.7	67
135	Effects of canagliflozin on cardiovascular risk factors in patients with type 2 diabetes mellitus. <i>International Journal of Clinical Practice</i> , 2017, 71, e12948.	0.8	20
136	Cardiovascular Protection by Sodium Glucose Cotransporter 2 Inhibitors: Potential Mechanisms. <i>American Journal of Cardiology</i> , 2017, 120, S28-S36.	0.7	45
137	Effect of Sodiumâ€Glucose Cotransportâ€2 Inhibitors on Blood Pressure in People With Type 2 Diabetes Mellitus: A Systematic Review and Metaâ€Analysis of 43 Randomized Control Trials With 22 528 Patients. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	226
138	Cardiovascular Protection by Sodium Glucose Cotransporter 2 Inhibitors: Potential Mechanisms. <i>American Journal of Medicine</i> , 2017, 130, S30-S39.	0.6	56
139	Spotlight on Canagliflozin 300: review of its efficacy and an indirect comparison to other SGLT-2 inhibitors and long-acting GLP-1 receptor agonists. <i>Expert Review of Clinical Pharmacology</i> , 2017, 10, 633-647.	1.3	2
140	Efficacy and safety of canagliflozin in patients with type 2 diabetes based on history of cardiovascular disease or cardiovascular risk factors: a post hoc analysis of pooled data. <i>Cardiovascular Diabetology</i> , 2017, 16, 40.	2.7	19
141	Efficacy and safety of gemigliptin, a dipeptidyl peptidaseâ€4 inhibitor, in patients with type 2 diabetes mellitus inadequately controlled with combination treatment of metformin and sulphonylurea: <sc>a</sc> 24â€week, multicentre, randomized, doubleâ€blind, placeboâ€controlled study (<sc>TROICA</sc> study). <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 635-643.	2.2	11
142	Liraglutide Versus SGLT-2 Inhibitors in People with Type 2 Diabetes: A Network Meta-Analysis. <i>Diabetes Therapy</i> , 2017, 8, 85-99.	1.2	19
143	Resolving the KgA1c paradox in the management of type 2 diabetes mellitus. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2017, 11, S159-S168.	1.8	0
144	Longer-term safety and tolerability of canagliflozin in patients with type 2 diabetes: a pooled analysis. <i>Current Medical Research and Opinion</i> , 2017, 33, 553-562.	0.9	30
145	Cost of Glycemic Target Achievement with Sodium Glucose Co-transporter 2 Inhibitors in Patients with Type 2 Diabetes in the UK. <i>Diabetes Therapy</i> , 2017, 8, 1175-1185.	1.2	3
146	Canagliflozin: A Review in Type 2 Diabetes. <i>Drugs</i> , 2017, 77, 1577-1592.	4.9	32

#	ARTICLE	IF	CITATIONS
147	The effect of SGLT2 inhibitors on cardiovascular events and renal function. <i>Expert Review of Clinical Pharmacology</i> , 2017, 10, 1251-1261.	1.3	9
148	Tolerability of canagliflozin in patients with type 2 diabetes mellitus fasting during Ramadan: Results of the Canagliflozin in Ramadan Tolerance Observational Study (CRATOS). <i>International Journal of Clinical Practice</i> , 2017, 71, e12991.	0.8	39
149	A Practical Approach to Hypertension Management in Diabetes. <i>Diabetes Therapy</i> , 2017, 8, 981-989.	1.2	17
150	SGLT2 inhibitors and risk of cancer in type 2 diabetes: a systematic review and meta-analysis of randomised controlled trials. <i>Diabetologia</i> , 2017, 60, 1862-1872.	2.9	134
151	The roles of sodium-glucose cotransporter 2 inhibitors in preventing kidney injury in diabetes. <i>Biomedicine and Pharmacotherapy</i> , 2017, 94, 176-187.	2.5	21
152	Canagliflozin in Conjunction With Sulfonylurea Maintains Glycemic Control and Weight Loss Over 52 Weeks: A Randomized, Controlled Trial in Patients With Type 2 Diabetes Mellitus. <i>Clinical Therapeutics</i> , 2017, 39, 2230-2242.e2.	1.1	17
153	Role of SGLT2 Inhibitors in Patients with Diabetes Mellitus and Heart Failure. <i>Current Heart Failure Reports</i> , 2017, 14, 275-283.	1.3	15
154	Cardiovascular outcomes with sodium-glucose cotransporter-2 inhibitors in patients with type II diabetes mellitus: A meta-analysis of placebo-controlled randomized trials. <i>International Journal of Cardiology</i> , 2017, 228, 352-358.	0.8	59
155	Healthcare costs of urinary tract infections and genital mycotic infections among patients with type 2 diabetes mellitus initiated on canagliflozin: a retrospective cohort study. <i>Journal of Medical Economics</i> , 2017, 20, 303-313.	1.0	8
156	Urinary tract and genital infections in patients with type 2 diabetes treated with sodium-glucose cotransporter 2 inhibitors: A meta-analysis of randomized controlled trials. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 348-355.	2.2	160
157	Fixed-Dose Combination of Canagliflozin and Metformin for the Treatment of Type 2 Diabetes: An Overview. <i>Advances in Therapy</i> , 2017, 34, 41-59.	1.3	20
158	<i>In vitro</i> and physiologically-based pharmacokinetic based assessment of drug-drug interaction potential of canagliflozin. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 1082-1096.	1.1	27
159	Effects of SGLT-2 inhibitors on mortality and cardiovascular events: a comprehensive meta-analysis of randomized controlled trials. <i>Acta Diabetologica</i> , 2017, 54, 19-36.	1.2	75
160	Canagliflozin improves risk factors of metabolic syndrome in patients with type 2 diabetes mellitus and metabolic syndrome. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2017, Volume 10, 47-55.	1.1	12
161	Effects of canagliflozin on weight loss in high-fat diet-induced obese mice. <i>PLoS ONE</i> , 2017, 12, e0179960.	1.1	53
162	Role of sodium glucose cotransporter-2 inhibitors in type I diabetes mellitus. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2017, Volume 10, 161-167.	1.1	7
163	An evidence-based practice-oriented review focusing on canagliflozin in the management of type 2 diabetes. <i>Vascular Health and Risk Management</i> , 2017, Volume 13, 43-54.	1.0	5
164	SGLT2 inhibitors and renal outcomes in type 2 diabetes with or without renal impairment: A systematic review and meta-analysis. <i>Primary Care Diabetes</i> , 2018, 12, 265-283.	0.9	62

#	ARTICLE	IF	CITATIONS
165	Japanese Clinical Practice Guideline for Diabetes 2016. <i>Journal of Diabetes Investigation</i> , 2018, 9, 657-697.	1.1	158
166	Impact of Canagliflozin Treatment on Health-Related Quality of Life among People with Type 2 Diabetes Mellitus: A Pooled Analysis of Patient-Reported Outcomes from Randomized Controlled Trials. <i>Patient</i> , 2018, 11, 341-352.	1.1	9
167	Pharmacokinetics and pharmacodynamics of canagliflozin in pediatric patients with type 2 diabetes. <i>Pediatric Diabetes</i> , 2018, 19, 649-655.	1.2	5
168	Achieving the composite endpoint of HbA1c, body weight, and systolic blood pressure reduction with canagliflozin in patients with type 2 diabetes. <i>Current Medical Research and Opinion</i> , 2018, 34, 313-318.	0.9	7
169	Pharmacotherapy of type 2 diabetes: An update. <i>Metabolism: Clinical and Experimental</i> , 2018, 78, 13-42.	1.5	144
170	Clinical potential of canagliflozin in cardiovascular risk reduction in patients with type 2 diabetes. <i>Vascular Health and Risk Management</i> , 2018, Volume 14, 419-428.	1.0	7
171	The Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Sympathetic Nervous Activity. <i>Frontiers in Endocrinology</i> , 2018, 9, 421.	1.5	84
172	Systematic Review of Efficacy and Safety of Newer Antidiabetic Drugs Approved from 2013 to 2017 in Controlling HbA1c in Diabetes Patients. <i>Pharmacy (Basel, Switzerland)</i> , 2018, 6, 57.	0.6	22
173	SGLT2 Inhibitors in Combination Therapy: From Mechanisms to Clinical Considerations in Type 2 Diabetes Management. <i>Diabetes Care</i> , 2018, 41, 1543-1556.	4.3	137
174	Japanese Clinical Practice Guideline for Diabetes 2016. <i>Diabetology International</i> , 2018, 9, 1-45.	0.7	215
175	Efficacy and safety of sodium-glucose cotransporter 2 inhibitors as add-on to metformin and sulfonylurea treatment for the management of type 2 diabetes: a meta-analysis. <i>Endocrine Journal</i> , 2018, 65, 335-344.	0.7	17
176	SGLT2 Inhibitors: A Review of Their Antidiabetic and Cardioprotective Effects. <i>International Journal of Environmental Research and Public Health</i> , 2019, 16, 2965.	1.2	153
177	The effect of SGLT-2 inhibitors on blood pressure: a pleiotropic action favoring cardio- and nephroprotection. <i>Future Medicinal Chemistry</i> , 2019, 11, 1285-1303.	1.1	15
178	Sodium-Glucose Cotransporter-2 Inhibitors, Reverse J-Curve Pattern, and Mortality in Heart Failure. <i>Heart Failure Clinics</i> , 2019, 15, 519-530.	1.0	2
179	Cardiovascular Outcomes in Trials of New Antidiabetic Drug Classes: A Network Meta-analysis. <i>SSRN Electronic Journal</i> , 2019, , .	0.4	0
180	Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Renal Outcomes in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>Scientific Reports</i> , 2019, 9, 13009.	1.6	60
181	Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial. <i>Lancet Diabetes and Endocrinology</i> , 2019, 7, 834-844.	5.5	149
182	The CANVAS Program: implications of canagliflozin on reducing cardiovascular risk in patients with type 2 diabetes mellitus. <i>Cardiovascular Diabetology</i> , 2019, 18, 64.	2.7	32

#	ARTICLE	IF	CITATIONS
183	A review of the mechanism of action, metabolic profile and haemodynamic effects of sodium-glucose co-transporter 2 inhibitors. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 9-18.	2.2	69
184	Comparative safety of the sodium glucose co-transporter 2 (SGLT2) inhibitors: a systematic review and meta-analysis. <i>BMJ Open</i> , 2019, 9, e022577.	0.8	144
185	Effect of SGLT2 inhibitor on renal function in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials. <i>International Urology and Nephrology</i> , 2019, 51, 655-669.	0.6	10
186	Hormonal, Metabolic and Hemodynamic Adaptations to Glycosuria in Type 2 Diabetes Patients Treated with Sodium-Glucose Co-Transporter Inhibitors. <i>Current Diabetes Reviews</i> , 2019, 15, 314-327.	0.6	11
187	Effect of canagliflozin use on body weight and blood pressure at one-year follow-up: A systematic review and meta-analysis. <i>European Journal of Preventive Cardiology</i> , 2019, 26, 1680-1682.	0.8	8
188	<p>&Canagliflozin review &ndash; safety and efficacy profile in patients with T2DM</p><p>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2019, Volume 12, 209-215.	1.1	30
189	Comparative efficacy of once-weekly semaglutide versus SGLT-2 inhibitors in patients inadequately controlled with one to two oral antidiabetic drugs: a systematic literature review and network meta-analysis. <i>BMJ Open</i> , 2019, 9, e023458.	0.8	11
190	Effects of SGLT2 inhibitors on cardiovascular outcomes and mortality in type 2 diabetes. <i>Medicine (United States)</i> , 2019, 98, e18245.	0.4	54
191	SGLT2 inhibitors and metformin: Dual antihyperglycemic therapy and the risk of metabolic acidosis in type 2 diabetes. <i>European Journal of Pharmacology</i> , 2019, 846, 23-29.	1.7	43
192	Factors influencing longitudinal changes of circulating liver enzyme concentrations in subjects randomized to placebo in four clinical trials. <i>American Journal of Physiology - Renal Physiology</i> , 2019, 316, G372-G386.	1.6	5
193	Effects of sodium-glucose cotransporter 2 inhibitors on risk of venous thromboembolism in patients with type 2 diabetes: A systematic review and meta-analysis. <i>Diabetes/Metabolism Research and Reviews</i> , 2020, 36, e3174.	1.7	8
194	Sodium-glucose cotransporter 2 (SGLT-2) inhibitors and microvascular outcomes in patients with type 2 diabetes: systematic review and meta-analysis. <i>Journal of Endocrinological Investigation</i> , 2020, 43, 289-304.	1.8	25
195	SGLT1 inhibition boon or bane for diabetes-associated cardiomyopathy. <i>Fundamental and Clinical Pharmacology</i> , 2020, 34, 173-188.	1.0	12
196	Effects of sodium-glucose co-transporter 2 inhibitors on liver parameters and steatosis: A meta-analysis of randomized clinical trials. <i>Diabetes/Metabolism Research and Reviews</i> , 2021, 37, e3413.	1.7	32
197	Efficacy of Modern Diabetes Treatments DPP-4i, SGLT-2i, and GLP-1RA in White and Asian Patients With Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials. <i>Diabetes Care</i> , 2020, 43, 1948-1957.	4.3	45
198	Japanese Clinical Practice Guideline for Diabetes 2019. <i>Journal of Diabetes Investigation</i> , 2020, 11, 1020-1076.	1.1	159
199	Japanese Clinical Practice Guideline for Diabetes 2019. <i>Diabetology International</i> , 2020, 11, 165-223.	0.7	266
200	SGLT2 inhibitors and atrial fibrillation in type 2 diabetes: a systematic review with meta-analysis of 16 randomized controlled trials. <i>Cardiovascular Diabetology</i> , 2020, 19, 130.	2.7	86

#	ARTICLE	IF	CITATIONS
201	Cost-utility analysis of second-line anti-diabetic therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin. <i>Current Medical Research and Opinion</i> , 2020, 36, 1619-1626.	0.9	3
202	Long-term renal outcomes associated with sodium glucose cotransporter 2 inhibitors in patients with type 2 diabetes mellitus: A systematic review and meta-analysis. <i>Diabetes/Metabolism Research and Reviews</i> , 2020, 36, e3303.	1.7	7
203	Effect of sodium-glucose co-transporter 2 inhibitors on lipid profile: A systematic review and meta-analysis of 48 randomized controlled trials. <i>Pharmacological Research</i> , 2020, 160, 105068.	3.1	56
204	Control of 24-hour blood pressure with SGLT2 inhibitors to prevent cardiovascular disease. <i>Progress in Cardiovascular Diseases</i> , 2020, 63, 249-262.	1.6	41
205	Comparative efficacy of sodium-glucose cotransporter-2 inhibitors (SGLT2i) for cardiovascular outcomes in type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials. <i>Heart Failure Reviews</i> , 2021, 26, 1421-1435.	1.7	26
206	Effect of Hemoglobin A1c Reduction or Weight Reduction on Blood Pressure in Glucagon-Like Peptide-1 Receptor Agonist and Sodium-Glucose Cotransporter-2 Inhibitor Treatment in Type 2 Diabetes Mellitus: A Meta-Analysis. <i>Journal of the American Heart Association</i> , 2020, 9, e015323.	1.6	22
207	Canagliflozin and cardiovascular outcomes in Type 2 diabetes. <i>Future Cardiology</i> , 2021, 17, 39-48.	0.5	1
208	Biocomputational Prediction Approach Targeting FimH by Natural SGLT2 Inhibitors: A Possible Way to Overcome the Uropathogenic Effect of SGLT2 Inhibitor Drugs. <i>Molecules</i> , 2021, 26, 582.	1.7	9
209	Effect of sodium-dependent glucose transporter inhibitors on glycated hemoglobin A1c after 24-weeks in patients with diabetes mellitus. <i>Medicine (United States)</i> , 2021, 100, e24101.	0.4	3
210	Effect of SGLT inhibitors on weight and lipid metabolism at 24-weeks of treatment in patients with diabetes mellitus. <i>Medicine (United States)</i> , 2021, 100, e24593.	0.4	12
211	Sodium/Glucose Cotransporter 2 Inhibitors and the Risk of Diabetic Ketoacidosis: An Example of Complementary Evidence for Rare Adverse Events. <i>American Journal of Epidemiology</i> , 2021, 190, 1572-1581.	1.6	8
212	Efficacy and Safety of Ertugliflozin in Patients with Type 2 Diabetes Inadequately Controlled by Metformin and Sulfonylurea: A Sub-Study of VERTIS CV. <i>Diabetes Therapy</i> , 2021, 12, 1279-1297.	1.2	7
213			
214	Systematic review and meta-analysis: SGLT2 inhibitors, blood pressure and cardiovascular outcomes. <i>IJC Heart and Vasculature</i> , 2021, 33, 100725.	0.6	18
215	Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and cardiac arrhythmias: a systematic review and meta-analysis. <i>Cardiovascular Diabetology</i> , 2021, 20, 100.	2.7	92
216	Canagliflozin: metabolic, cardiovascular and renal protection. <i>Future Cardiology</i> , 2021, 17, 443-458.	0.5	5
217	SGLT-2i and Risk of Malignancy in Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials. <i>Frontiers in Public Health</i> , 2021, 9, 668368.	1.3	13
218	Could Sodium/Glucose Co-Transporter-2 Inhibitors Have Antiarrhythmic Potential in Atrial Fibrillation? Literature Review and Future Considerations. <i>Drugs</i> , 2021, 81, 1381-1395.	4.9	10

#	ARTICLE	IF	CITATIONS
219	Combined medical strategies for the management of type 2 diabetes mellitus and obesity in adults. Expert Opinion on Pharmacotherapy, 2021, 22, 1-22.	0.9	2
220	Canagliflozin for Prevention of Cardiovascular and Renal Outcomes in type2 Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Frontiers in Pharmacology, 2021, 12, 691878.	1.6	8
221	The Na/K-ATPase Signaling and SGLT2 Inhibitor-Mediated Cardiorenal Protection: A Crossed Road?. Journal of Membrane Biology, 2021, 254, 513-529.	1.0	7
222	Sodium-glucose cotransporter 2 inhibitors for the management of type 2 diabetes. Expert Opinion on Pharmacotherapy, 2021, 22, 2181-2198.	0.9	2
223	Sodium-Glucose Co-Transporter Inhibitors and Atrial Fibrillation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Journal of the American Heart Association, 2021, 10, e022222.	1.6	38
224	Sodium-Glucose Cotransporter 2 Inhibitors, All-Cause Mortality, and Cardiovascular Outcomes in Adults with Type 2 Diabetes: A Bayesian Meta-Analysis and Meta-Regression. Journal of the American Heart Association, 2021, 10, e019918.	1.6	8
225	SGLT inhibitors as antidiabetic agents: a comprehensive review. RSC Advances, 2020, 10, 1733-1756.	1.7	20
226	Canagliflozin lowers blood sugar, but does it also lower cardiovascular risk? Maybe not. Annals of Translational Medicine, 2017, 5, 473-473.	0.7	2
227	The Beneficial Hemodynamic Actions of SGLT-2 Inhibitors beyond the Management of Hyperglycemia. Current Medicinal Chemistry, 2020, 27, 6682-6702.	1.2	16
228	Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Korean Patients with Type 2 Diabetes Mellitus in Real-World Clinical Practice. Diabetes and Metabolism Journal, 2019, 43, 590.	1.8	20
229	Efficacy and safety of canagliflozin among patients with type 2 diabetes mellitus: A systematic review and meta-analysis. Indian Journal of Endocrinology and Metabolism, 2015, 19, 705.	0.2	8
230	Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus from India. Indian Journal of Endocrinology and Metabolism, 2016, 20, 372.	0.2	16
231	A review of clinical efficacy and safety of canagliflozin 300 mg in the management of patients with type 2 diabetes mellitus. Indian Journal of Endocrinology and Metabolism, 2017, 21, 196.	0.2	10
232	Sodium glucose co-transporter-2 inhibitor: Benefits beyond glycemic control. Indian Journal of Endocrinology and Metabolism, 2019, 23, 140.	0.2	7
233	Effects of rifampin, cyclosporine A, and probenecid on the pharmacokinetic profile of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in healthy participants. International Journal of Clinical Pharmacology and Therapeutics, 2015, 53, 115-128.	0.3	34
234	Effects of sodium-glucose co-transporter 2 (SGLT2) inhibition on renal function and albuminuria in patients with type 2 diabetes: a systematic review and meta-analysis. PeerJ, 2017, 5, e3405.	0.9	32
235	Adding Sodium-Glucose Co-Transporter 2 Inhibitors to Sulfonylureas and Risk of Hypoglycemia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Frontiers in Endocrinology, 2021, 12, 713192.	1.5	1
236	Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors in Type 2 Diabetes: A Literature Review of Approved Products. Pharmacology & Pharmacy, 2014, 05, 1029-1058.	0.2	0

#	ARTICLE	IF	CITATIONS
237	Who is the Ideal Candidate for Canagliflozin?. Internal Medicine: Open Access, 2014, 04, .	0.0	0
238	Canagliflozin in the treatment of diabetes: Perspectives. Diabesity, 2015, 1, 7.	0.1	0
239	Flavonoids. Advances in Medical Education, Research, and Ethics, 2016, , 286-328.	0.1	1
240	Canagliflozin-inhibitor SGLT2 in diabetes mellitus therapy. Interni Medicina Pro Praxi, 2016, 18, 103-106.	0.0	0
241	SGLT2 Inhibitors for Treating Diabetes. , 2017, , 13-35.		0
242	Comparative analysis of quality of life in patients treated with canagliflozine or DPP-IV inhibitor. Diabetes Mellitus, 2016, 19, 511-517.	0.5	0
244	Flavonoids. , 2017, , 569-612.		0
245	EFFICACY OF CANAGLIFLOZIN AS AN ADD-ON TO TRIPLE DRUG TREATMENT WITH GLIMEPIRIDE, METFORMIN AND TENELIGLIPTIN. Journal of Evidence Based Medicine and Healthcare, 2018, 5, 2042-2046.	0.0	0
246	Effects of canagliflozin are mostly observed at first follow-up, within 6 months of commencement: results for the ABCD canagliflozin audit. British Journal of Diabetes, 2020, 20, 113-116.	0.1	0
247	Does SGLT2 Inhibition Affect Sympathetic Nerve Activity in Type 2 Diabetes?. Hormone and Metabolic Research, 2021, 53, 75-84.	0.7	5
248	Evaluating Drug Cost per Response with SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus. American Health and Drug Benefits, 2015, 8, 309-18.	0.5	16
250	Association of SGLT2 Inhibitors With Risk of Atrial Fibrillation and Stroke in Patients With and Without Type 2 Diabetes: A Systemic Review and Meta-Analysis of Randomized Controlled Trials. Journal of Cardiovascular Pharmacology, 2022, 79, e145-e152.	0.8	27
251	Novel Approaches to Restore Pancreatic Beta-Cell Mass and Function. Handbook of Experimental Pharmacology, 2021, , 439-465.	0.9	1
252	Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO). Nutrition, Metabolism and Cardiovascular Diseases, 2022, 32, 1-16.	1.1	15
254	Comparative Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Serum Electrolyte Levels in Patients with Type 2 Diabetes: A Pairwise and Network Meta-Analysis of Randomized Controlled Trials. Kidney360, 2022, 3, 477-487.	0.9	16
255	Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO). Digestive and Liver Disease, 2022, 54, 170-182.	0.4	12
256	Dose-ranging effects of SGLT2 inhibitors in patients with type 2 diabetes: a systematic review and meta-analysis. Archives of Endocrinology and Metabolism, 2022, 66, 68-76.	0.3	6
257	Effects of different doses of canagliflozin on blood pressure and lipids in patients with type 2 diabetes: a meta-analysis. Journal of Hypertension, 2022, 40, 996-1001.	0.3	4

#	ARTICLE	IF	CITATIONS
258	Comparison of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-like Peptide Receptor Agonists for Atrial Fibrillation in Type 2 Diabetes Mellitus: Systematic Review With Network Meta-analysis of Randomized Controlled Trials. <i>Journal of Cardiovascular Pharmacology</i> , 2022, 79, 281-288.	0.8	15
259	SGLT2 Inhibitors in Type 2 Diabetes Mellitus and Heart Failure—A Concise Review. <i>Journal of Clinical Medicine</i> , 2022, 11, 1470.	1.0	16
260	Effects of Sodium-Glucose Cotransporter-2 Inhibitors on Weight in Type 2 Diabetes Mellitus and Therapeutic Regimen Recommendation. <i>Journal of Diabetes Research</i> , 2022, 2022, 1-13.	1.0	3
261	Comparative Cardiovascular Outcomes of SGLT2 Inhibitors in Type 2 Diabetes Mellitus: A Network Meta-Analysis of Randomized Controlled Trials. <i>Frontiers in Endocrinology</i> , 2022, 13, 802992.	1.5	16
262	Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO). <i>Eating and Weight Disorders</i> , 2022, 27, 1603-1619.	1.2	9
263	Effect of sodium-glucose cotransporter-2 (SGLT2) inhibitors on serum urate levels in patients with and without diabetes: a systematic review and meta-regression of 43 randomized controlled trials. <i>Therapeutic Advances in Chronic Disease</i> , 2022, 13, 204062232210835.	1.1	19
264	Diabetes: how to manage overweight and obesity in type 2 diabetes mellitus. <i>Drugs in Context</i> , 0, 11, 1-12.	1.0	3
265	Putative protective effects of sodium-glucose cotransporter 2 inhibitors on atrial fibrillation through risk factor modulation and off-target actions: potential mechanisms and future directions. <i>Cardiovascular Diabetology</i> , 2022, 21, .	2.7	8
266	Vibration of effect in more than 16 000 pooled analyses of individual participant data from 12 randomised controlled trials comparing canagliflozin and placebo for type 2 diabetes mellitus: multiverse analysis. , 2022, 1, e000154.		3
267	Sodium-Glucose Cotransporter 2 Inhibitors and the Risk of Pneumonia and Septic Shock. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, 3442-3451.	1.8	7
268	Mechanism of canagliflozin-induced vasodilation in resistance mesenteric arteries and the regulation of systemic blood pressure. <i>Journal of Pharmacological Sciences</i> , 2022, 150, 211-222.	1.1	4
269	Risk of hypovolemia associated with sodium-glucose cotransporter-2 inhibitors treatment: A meta-analysis of randomized controlled trials. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	4
270	Effect of sodium-glucose co-transporter 2 inhibitors on plasma potassium: A meta-analysis. <i>Diabetes Research and Clinical Practice</i> , 2023, 196, 110239.	1.1	4
271	External control arm analysis: an evaluation of propensity score approaches, G-computation, and doubly debiased machine learning. <i>BMC Medical Research Methodology</i> , 2022, 22, .	1.4	3
272	Quantitative analysis of low content polymorphic impurities in canagliflozin tablets by PXRD, NIR, ATR-FITR and Raman solid-state analysis techniques combined with stoichiometry. <i>Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy</i> , 2023, 293, 122458.	2.0	1